NYXH

BEARISH

$3.38 Live

Nyxoah SA · NASDAQ

Target $10.46 (+209.8%)

$2.76 52W Range $8.64

NYXH Nyxoah SA - Fundamental Analysis

BEARISH

Console Chart News

NYXH Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Medical Instruments & Supplies

Current Price Live

$3.38

Analyst Target

$10.46

+209.8% Upside

52W High

$8.64

52W Low

$2.76

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 16, 2026

Market cap

$147.36M

P/E

N/A

ROE

-111.0%

Profit margin

N/A

Debt/Equity

0.86

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

NYXH exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company shows explosive revenue growth (346.90% YoY) and maintains a strong gross margin of 63.13%, these are overshadowed by an unsustainable operating margin of -329.29% and a consistent track record of earnings misses. The stock is technically in a freefall with a 0/100 trend score and a 1-year price decline of 43.6%. Despite bullish analyst price targets, the deterministic data suggests a high-risk speculative profile with significant capital erosion.

Key Strengths

Hyper-growth in revenue (346.90% YoY)

Strong Gross Margin (63.13%) indicating product value

Manageable Debt/Equity ratio (0.86)

Positive analyst sentiment with a high target price ($10.46)

Current ratio above 1.0 (1.25), providing minimal short-term liquidity

Key Risks

Extreme cash burn reflected in -329.29% operating margin

Critical fundamental health (Piotroski F-Score 1/9)

Severe negative price momentum (0/100 Technical Trend)

High valuation relative to sales (P/S 14.71) for a non-profitable entity

Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

High-Risk Speculative

Key drivers: Extreme revenue growth, Catastrophic operating losses, Severe technical breakdown, Critical F-Score

Confidence

90%

Value

15/100

P/S 14.71, Forward P/E -2.22

Positives

Low market cap provides high upside potential if pivoted

Watchpoints

P/S ratio of 14.71 is excessive for current profitability
No Graham Number available due to lack of earnings

Future

55/100

Ref Revenue Growth vs EPS Growth

Positives

Exceptional YoY revenue growth (346.90%)
Strong analyst target price ($10.46)

Watchpoints

Earnings growth is negative (-28.3% YoY)
Operating losses are widening

Past

10/100

Ref 1Y, 3Y, 5Y Price Change

Positives

Recent 1-week bounce (+11.4%)

Watchpoints

5-year return of -85.9%
Consistent earnings misses over 20 quarters

Health

12/100

Ref Piotroski F-Score 1/9

Positives

Debt/Equity is lower than sector average

Watchpoints

Piotroski F-Score 1/9 indicates extreme weakness
ROE of -110.95% shows massive equity erosion

Dividend

0/100

Ref Dividend Yield N/A

Positives

No standout positives identified.

Watchpoints

No dividend paid
No capacity for dividends given losses

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$3.38

Analyst Target

$10.46

Upside/Downside

+209.8%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for NYXH and closest competitors.

Updated 2026-04-15

Company	5Y	3Y	1Y	6M	1M	1W
NYXH Nyxoah SA Primary	-85.9%	-65.9%	-43.6%	-44.6%	+7.1%	+11.4%
APYX Apyx Medical Corporation Peer	-68.5%	+28.3%	+249.0%	+72.9%	-7.4%	+16.4%
AGEN Agenus Inc. Peer	-93.5%	-88.0%	+124.2%	-10.7%	+36.6%	+18.4%
EMPG Empro Group Inc. Peer	+299.1%	+299.1%	+299.1%	-2.2%	0.0%	0.0%
RCEL AVITA Medical, Inc. Peer	-74.5%	-65.7%	-44.2%	+28.8%	+22.7%	+2.6%

NYX

Nyxoah SA

Primary

-85.9%

-65.9%

-43.6%

-44.6%

+7.1%

+11.4%

APY

Apyx Medical Corporation

Peer

-68.5%

+28.3%

+249.0%

+72.9%

-7.4%

+16.4%

AGE

Agenus Inc.

Peer

-93.5%

-88.0%

+124.2%

-10.7%

+36.6%

+18.4%

EMP

Empro Group Inc.

Peer

+299.1%

-2.2%

0.0%

RCE

AVITA Medical, Inc.

Peer

-74.5%

-65.7%

-44.2%

+28.8%

+22.7%

+2.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-2.22

N/A

2.53

14.71

14.12

-1.72

$147.36M

Profitability

Profit margins and return metrics

Profit Margin N/A

Operating Margin -329.29%

Gross Margin 63.13%

ROE -110.95%

ROA -37.67%

Growth

Revenue and earnings growth rates

Revenue Growth +346.9%

Earnings Growth N/A

Q/Q Revenue Growth +346.87%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.86

Moderate

Current Ratio

1.25

Good

Quick Ratio

1.14

Good

Cash/Share

$1.1

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Gross Margin

64.2%

Op. Margin

-323.5%

Net Margin

-416.6%

Total Assets

$0.1B

Liabilities

$0.1B

Equity

$0.0B

Debt/Equity

1.41x

Operating CF

$-0.0B

CapEx

$-0.0B

Free Cash Flow

$-0.0B

FCF Yield

109%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-12

$N/A

2026-03-19

$-0.59

-6.6% surprise

2025-11-13

$-0.63

-11.8% surprise

2025-08-18

$-0.55

+3.2% surprise

Healthcare Sector Comparison

Comparing NYXH against 421 companies in the Healthcare sector (25 bullish, 134 neutral, 262 bearish)

Return on Equity (ROE)

-110.95%

This Stock

-100.15%

Sector Avg

+10.8% (Excellent)

Debt to Equity

0.86

This Stock

3.22

Sector Avg

-73.4% (Less Debt)

Revenue Growth

346.9%

This Stock

121.05%

Sector Avg

+186.6% (Fast Growth)

Current Ratio

1.25

This Stock

4.55

Sector Avg

-72.5% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
NYXH Nyxoah SA	BEARISH	$147.36M	-	-111.0%	-%	$3.38
APYX Apyx Medical Corporation	BULLISH	$148.94M	-	-76.1%	-21.2%	$3.63	Compare
AGEN Agenus Inc.	BEARISH	$144.21M	-	-%	-32.9%	$3.99	Compare
EMPG Empro Group Inc.	NEUTRAL	$143.05M	192.89	66.3%	13.7%	$17.36	Compare
RCEL AVITA Medical, Inc.	BEARISH	$157.45M	-	-%	-67.8%	$5.14	Compare

NYXH Nyxoah SA

BEARISH

Mkt Cap

$147M

P/E

ROE

-111.0%

Price

$3.38

Compare with NYXH

Compare with NYXH

EMPG Empro Group Inc.

Compare with NYXH

RCEL AVITA Medical, Inc.

Compare with NYXH

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

BUY

4 analysts

Stifel

2026-04-10

Maintains

Buy Buy

Cantor Fitzgerald

2026-03-23

reit

Overweight Overweight

Stifel

2026-03-20

Maintains

Buy Buy

Stifel

2026-01-29

Maintains

Buy Buy

Piper Sandler

2025-11-14

reit

Overweight Overweight

Past News Coverage

Recent headlines mentioning NYXH from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

NYXH

NYXH Nyxoah SA - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!